HopeStage
Back to all studies
CompletedNCT06315283

TV-44749 comparison with olanzapine in schizophrenia

About this titleRead the official source — NCT06315283
Medication studyAges 18–64Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations
Los Alamitos and 8 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 20, 2024
Recruitment status
Completed
Enrollment listed in the registry
153
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States, United Kingdom, Croatia, ...
Age range
From 18 Years to 64 Years
Official registry ID
NCT06315283
Official title
Show the full official title

A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Alamitos, United States · Torrance, United States · Hollywood, United States

6 more locations
  • Atlanta, United States
  • Decatur, United States
  • Marlton, United States
  • Zagreb, Croatia
  • Zamora, Spain
  • Surrey, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Teva Branded Pharmaceutical Products R&D LLC, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including TV-44749 and Oral olanzapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies